Andrew J. Armanino - 10 Apr 2023 Form 4 Insider Report for Better Therapeutics, Inc.

Role
Director
Signature
/s/ Mark Heinen, Attorney-in-Fact
Issuer symbol
BTTX on OTC
Transactions as of
10 Apr 2023
Net transactions value
+$250,000
Form type
4
Filing time
12 Apr 2023, 16:15:09 UTC
Previous filing
02 Feb 2023
Next filing
03 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock Purchase $250,000 +303,030 +200% $0.8250 454,358 10 Apr 2023 By Armanino Trust F1, F2, F3
holding BTTX Common Stock 13,334 10 Apr 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 6, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the "PIPE Investors") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $0.825 per share. As one of the PIPE Investors, the Reporting Person acquired 303,030 shares of Issuer common stock on April 10, 2023 for $0.825 per share.
F2 The Reporting Person no longer has a reportable beneficial interest in 15,000 shares of Issuer common stock owned by his son and included in the Reporting Person's prior ownership report on Form 4.
F3 These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust"), and indirectly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust.